In current study, we showed that one of ErbB3 binding partner p42 induces degradation of p85 subunit, which is the other ErbB3 binding partner, and subsequently decreased cancerous growth and invasion in MCF7 and MDA-MB231 breast cancer cell lines and notably reduced tumor size in xenograft model. Here, ERBB3 is linked to neoplasm.